
Rockwell Medical, Inc.
RMTINASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$7.65
−US$0.45 · -5.56%
RMTI公司概覽
盤中時間採用ET。市場資料可能有所延遲。
GoAI 研究快照
簡明呈現最新可用的模型資訊。
GoAI評分
Sell
Trim exposure — unfavorable risk-reward
估值
50
Fair Value
動能
17
Strong Down
情緒
59
Mixed
風險韌性
23
High Risk
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
人工智慧產生的上下文僅供參考,並非投資建議。
公司概況
公司網站Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.
- 產業
- Drug Manufacturers - Specialty & Generic
- 部門
- Healthcare
- 總部
- US
- 執行長
- Mark Strobeck
- 上市以來
- 1998年1月27日
- 僱員
- 157
市場位置
- 成交量
- 9845.81
- 0.29× 平均值
- 平均成交量
- 3.35萬
- 日均成交量
- 市值
- 3019.48萬 USD
- 貝塔
- 1.62
- 市場參考 1
RMTI同業公司
繼續GoAI的研究
在 GoAI 中研究RMTIresearch.disclaimer





